中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 2024 年年度股东大会的法律意见书 致：华熙生物科技股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称"《股 东会规则》")等法律、法规及规范性文件和《华熙生物科技股份有限公司章程》 (以下简称"《公司章程》")的规定，北京市通商律师事务所(以下简称"通商" 或"本所")接受华熙生物科技股份有限公司(以下简称"公司")委托，指派本所 律师出席了公司于 2025 年 6 月 11 日召开的 20 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-021 华熙生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 06 月 11 日 （二） 股东大会召开的地点：浙江省杭州市钱塘区海达北路 399 号康洲科创园 B1 座 1 层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 188 | | --- | --- | | 普通股股东人数 | 188 | | 2、出席会议的股东所持有的表决权数量 | 302,670,369 | | 普通股股东所持有表决权数量 | 302,670,369 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 63.2721 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 63.2 ...

值得注意的是，近年来，相宜本草管理层变动已经成为常态。据北京商报记者粗略统计，近十年的发展 中，相宜本草先后有4位CEO离职，期间还不断出现其他高层的离职。当同时期成长起来的竞争对手都 成功登陆资本市场并开启更为长远的战略发展，慢一拍的相宜本草越发焦虑。 频换高管、上市无果 上市动作没有再进一步，相宜本草的高管变动却没有停止。据北京商报记者不完全统计，在近十年的发 展中，相宜本草先后有4位CEO离职。其中就包括，今年3月，任职仅7个月时间的CEO张舸离职；2024 年6月，相宜本草CEO兼总裁俞巍宣布离职。在此期间，相宜本草还先后经历了副总经理、CS事业部总 经理、销售副总裁、首席营销官等多位高管离职。 相宜本草再次出现高管变动。6月11日，北京商报记者了解到，相宜本草研发副总裁兼首席科学家吕智 离职。相宜本草方面对上述消息未作出任何官方回应，有媒体从吕智本人处确认其已不再担任相宜本草 研发副总裁一职，但依然是相宜本草的股东，并保留了首席科学家的职位。 关于管理层人事变动相关问题，北京商报记者对相宜本草进行采访，但截至发稿未收到回复。 在业界猜测中，相宜本草对于内部管理层的频繁调整，多少反映出其十年上市未果的 ...

Core Viewpoint - The beauty industry is experiencing a surge in interest in PDRN (Polydeoxyribonucleotide), with numerous domestic and international brands launching products featuring this ingredient, indicating a promising market outlook for PDRN in the coming years [2][3][5]. Group 1: Market Trends and Growth - The global PDRN market was approximately 180 million yuan in 2023 and is expected to reach 3 billion yuan by 2030, with a compound annual growth rate (CAGR) of 43% from 2024 to 2030 [2]. - Currently, there are 3,894 brands using PDRN, with 16,901 products containing this ingredient, showing rapid growth in the market [5]. - The PDRN market is characterized by a diverse range of players, including domestic brands like Zhanmei Ya and international giants like L'Oréal and Amorepacific, all actively entering the PDRN space [2][6][13]. Group 2: Product Innovations and Technologies - Zhanmei Ya's "Ball PDRN Energy Stick" achieved over 10 million in sales within a month of launch, highlighting the strong consumer demand for PDRN products [7]. - Various brands are employing innovative technologies to enhance PDRN's effectiveness, such as microencapsulation and lactobacillus vesicle technology, to improve skin absorption [29][30]. - PDRN is being integrated into a wide range of products, including serums and creams, with brands like CNP and Lancôme emphasizing its clinical-grade efficacy [9][11][30]. Group 3: Scientific Basis and Mechanisms - PDRN has a long history of use in the beauty industry, with established benefits in skin repair and regeneration, supported by over 600 research publications [14][23]. - The mechanism of PDRN involves promoting cell proliferation and regulating inflammatory responses, making it a valuable ingredient for anti-aging and skin repair [23][24]. - PDRN's unique properties, such as its non-antigenic nature and low toxicity, contribute to its safety and effectiveness in cosmetic applications [21][23]. Group 4: Challenges and Future Prospects - Despite its popularity, PDRN faces challenges related to its large molecular size and poor transdermal absorption, which are critical for its effectiveness in topical applications [29][30]. - The market is witnessing a trend towards artificial synthesis of PDRN, which could enhance production consistency and reduce costs, making it more accessible [39][41]. - As the market matures, there is a need for better consumer education regarding PDRN's benefits and limitations to avoid misconceptions about its efficacy [33][35].

Core Insights - The overall brand communication effectiveness of Shandong listed companies showed improvement in April 2025, with an average INC index of 588.49, reflecting a 0.43% increase from March [1][3] - The company with the highest increase in ranking was Zhongchuang Logistics Co., Ltd., which rose by 156 positions, while Zhiyang Innovation Technology Co., Ltd. experienced the largest drop, falling by 132 positions [1] INC Index Overview - The INC index, or Internet Communication Influence Index, serves as a quantitative evaluation system for brand communication effectiveness in the digital age [2] - The index evaluates dimensions such as communication breadth, heat, online attention, and official website presentation [2] Industry Level Analysis - The average INC index of 588.49 indicates that most brands in the industry are maturing and gaining more attention, with both brand voice and social concern on the rise [3] - The skewness coefficient of the INC index is 0.77, indicating a moderate right-skewed distribution, where a few units exhibit outstanding communication influence, enhancing the overall industry INC level [3] Communication Breadth Analysis - The average communication breadth index for April was 2.73, categorized as "standard level" [5] - Eight companies achieved the highest level (5), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [5] - A total of 68 companies reached level 4 ("upgraded level"), while 212 companies were at level 3 ("standard level") [5] Communication Heat Analysis - The average communication heat index was 2.36, also at the "standard level" [6] - Five companies reached the highest level (5), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [7] - A total of 50 companies achieved level 4, indicating strong activity and high information engagement [7][8] Online Attention Analysis - The average online attention index was 1.6, categorized as "regional attention" [9] - 107 companies reached level 3 or above ("national attention"), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [10] - 114 companies were at the lowest level ("sporadic attention"), indicating low brand awareness [10] Official Website Presentation Analysis - The average official website presentation index was 1.08, below the "standard level" [11] - Two companies achieved the highest level (5), including Haier Smart Home Co., Ltd. [12] - A total of 176 companies were at the lowest level ("deep water level"), indicating poor website visibility [12]

来源：中国新闻网 中新网兰州6月11日电 (张婧 程涛)在甘肃省临夏县的山间地头，这片位于黄土高原与青藏高原过渡带的 县域，7.5万亩啤特果树正舒展枝叶。这种形似梨、味甘涩的西北特有果实，曾是临夏县的生态底色， 亦是当地农民增收的传统依托。 但长期以来，鲜果销售的单一模式让产业陷入"靠天吃饭"的困局。如何让"绿叶子"变成"金果子"？临夏 县将目光投向千里之外的山东省济南市高新区，那里有一家全球玻尿酸行业龙头企业华熙生物科技股份 有限公司。 5月底，位 于甘肃省临夏回族自治州临夏县的一家生物科技公司生产车间内，进行啤特果原液生产。汤晓亮 摄 与济南高新区对接中，临夏县了解到上述公司的生物科技研发能力，经过前期调研，双方决定以啤特果 原液为核心开发护肤产品。作为甘鲁两省重点产业协作项目，合作成立华熙济高生物科技(甘肃)有限公 司，是甘肃省首家化妆品新原料生产企业。 华熙济高生物科技(甘肃)有限公司副总经理尹始杰说，为了实现全产业链生产的目标，投入东西部协作 资金4100万元，提升改造项目厂房及仓库改建，啤特果原液生产设备均已落位安装，目前正在有序调试 生产设备。预计2025年8月投产，当年可实现产值1000万元， ...

Core Viewpoint - The ongoing dispute between Juzi Biotech and Huaxi Biotech highlights significant issues within the domestic beauty industry, including unclear standards and a crisis of consumer trust [4][7][26]. Group 1: Company Developments - Juzi Biotech's major shareholder announced plans to increase its stake in the company by at least 200 million HKD, leading to a temporary stock price increase of 4.15% [3][18]. - Despite the initial stock price rise, Juzi Biotech's shares fell again shortly after, indicating a lack of sustained investor confidence [4][5]. - In contrast, Huaxi Biotech reported a significant decline in revenue and profit, with a revenue of 5.317 billion RMB, down 11.61% year-on-year, and a net profit drop of 70.59% to 174 million RMB [22][25]. Group 2: Market Dynamics - The competition between Huaxi Biotech and Juzi Biotech has drawn attention to the effectiveness of hyaluronic acid versus the emerging trend of recombinant collagen, with predictions indicating that the collagen market could surpass hyaluronic acid by 2026 [19][25]. - Juzi Biotech's revenue reached 5.539 billion RMB, a year-on-year increase of 57.17%, while its net profit grew by 42.4% to 2.062 billion RMB [22][25]. Group 3: Industry Issues - The dispute has revealed a lack of rigorous standards and clear definitions in the beauty industry, contributing to consumer skepticism [7][26]. - Industry insiders have pointed out that the marketing strategies often overshadow research and development, with Juzi Biotech's R&D expenditure being significantly lower than that of its competitors [27][29]. - The ongoing debate over ingredient efficacy may serve as a catalyst for improved transparency and standards within the industry, potentially benefiting consumers and companies alike [29][30].

Core Viewpoint - Lin Qingxuan, a domestic skincare brand, has officially initiated its IPO process by submitting a prospectus to the Hong Kong Stock Exchange, aiming for a valuation of approximately 38.26 billion RMB with a projected revenue of 1.209 billion RMB and a net profit of 187 million RMB for 2024 [2][15]. Financial Performance - In 2024, Lin Qingxuan's revenue is expected to reach 1.209 billion RMB, with a net profit of 187 million RMB, marking a significant increase from a loss of 5.93 million RMB in 2022 [2][15]. - The company's revenue structure remains heavily reliant on direct sales, with 398 million RMB from direct stores, accounting for over 90% of total revenue, while income from franchise and joint venture stores is only 45.76 million RMB [3][5]. Market Positioning - Lin Qingxuan positions itself as a high-end brand, comparable to foreign brands, but faces challenges in establishing a strong market presence and brand recognition in high-end retail environments [8][14]. - The brand's gross margin stands at 86% for direct stores, significantly higher than the 71.5% for cooperative stores, indicating a disparity in profitability between the two sales channels [5][13]. Growth Strategy - The company has opened its franchise system in 2023 to accelerate offline expansion, but the results have not yet yielded significant revenue growth, with franchise and joint venture stores showing lower efficiency compared to direct stores [3][7]. - Lin Qingxuan's future growth strategy will focus on optimizing its joint venture model and enhancing product development and financial structure to support long-term valuation [2][15]. Competitive Landscape - Compared to competitors like Maogeping, Lin Qingxuan's market share and positioning in the high-end skincare segment are still developing, with both brands claiming to be the only domestic brands competing with foreign counterparts [8][11]. - The brand's R&D investment is relatively low at 2.56% of revenue, which is below industry leaders, indicating a need for increased investment in innovation to strengthen its high-end positioning [14]. Leadership and Market Sentiment - The founder, Sun Laichun, has significantly influenced the brand's growth through active participation in live-streaming sales, which has raised concerns about the sustainability of this growth model [15][16]. - Recent market trends show a recovery in the Hong Kong consumer sector, providing a favorable environment for Lin Qingxuan's IPO, as other beauty brands have seen their stock prices double [17].

Core Insights - The Chinese beauty market is experiencing significant growth driven by ingredient-focused marketing, but there is a widening gap between consumer expectations and regulatory standards [1] - The complexity of new ingredients like bioactive peptides and plant extracts has outpaced existing national standards, leading to regulatory challenges [1][7] - Social media's promotion of high-concentration ingredients has resulted in consumer misconceptions about safety and efficacy, increasing the risk of health issues [1] Group 1: Medical Applications - Hyaluronic acid (HA) is primarily used for facial filling and shaping, addressing issues like wrinkles and volume loss, while collagen is crucial for skin firmness and elasticity [2][3] - HA provides immediate results and strong moisturizing effects, but its effects last only 6-12 months, requiring regular maintenance [4] - Collagen injections take longer to show results (1-2 weeks) but can stimulate the body's own collagen production, with effects lasting 6-18 months or longer [5] Group 2: Market Dynamics - HA dominates the aesthetic filler market due to lower production costs and widespread application, while collagen's market share is smaller but growing faster [8][9] - The production cost of collagen is 3-5 times higher than that of HA, which contributes to its higher retail price [8] - High prices for collagen may slow its market penetration, particularly in emerging markets, but some consumers view the cost as a reflection of quality [9] Group 3: Regulatory and Testing Standards - Current testing methods for HA include high-performance liquid chromatography (HPLC) and gel permeation chromatography (GPC), while collagen is tested using methods like the Kjeldahl method and BCA assay [6][7] - Regulatory focus is on purity, molecular weight distribution, and biological safety, with HA standards being more established than those for collagen [7] - The rapid development of new materials outpaces the evolution of traditional quality standards, posing challenges for regulatory compliance [7] Group 4: Future Trends - The next five years may see increased integration of HA and collagen in applications aimed at improving skin hydration and elasticity [10] - Innovations in synthetic biology could lead to breakthroughs in the use of collagen in tissue engineering and regenerative medicine [10] - As competition intensifies, prices for both HA and collagen products may decrease, driven by technological advancements and market entry of new players [11]

瑞财经 钟鸣辰2025年6月6日至8日，第六届"和君小镇·中国上市公司董秘论坛"在江西会昌和君小镇盛大 举行。论坛由江西省科学院、华东师范大学产业技术研究院、和君集团、和君职业学院联合主办，和君 董秘邦、和君小镇承办。论坛围绕科技、消费、出海、并购重组、股票投资等五大主题展开，点明机 会、呈现前途。 蜜雪冰城、伊利股份、吉利汽车、华熙生物、华大智造、天元宠物、安必平等200多家上市公司和拟上 市公司董秘和高管参加了论坛，这些公司的市值累计超过一万亿元人民币。 同时参会的还有华夏基金、沙特阿美战略投资、中海油基金、美的资本、深创投、元禾资本等30多家投 资机构的管理者及合伙人，这些投资机构管理的资本规模累计超过二万亿元人民币。 两个"万亿规模"，构成本届论坛的基本含金量。而出席论坛的20多位演讲嘉宾和广大参会者的思想见 地、专业水准和能力经验，更是无价之宝。 "2025年，经济大势怎么看、产业趋势怎么走、上市公司怎么干、股票投资怎么选？"是本届"和君小镇· 中国上市公司董秘论坛"的主题，也是广大上市公司、投资机构和政府招商引资部门的共同关切。论坛 由四场内容构成： 第一场是"科技与产业"，院士、科学家和企业家代 ...